Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 10;34(9):1513–1520. doi: 10.1681/ASN.0000000000000186

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 by the American Society of Nephrology

PMC Copyright notice

Figure 1. — Overall survival and other markers of excretory kidney function; albuminuria and other markers of kidney barrier function. (A) Percentage reaching primary end point (overall survival) of WT, CKD-veh, CKD-RASi, CKD-RASi/SGLT2i, and CKD-RASi/SGLT2i/MRA groups. (B) Effects of RASi, RASi/SGLT2i, and RASi/SGLT2i/MRA treatments on GFR. (C) Body weight changes after 6 weeks (shown as a percentage of initial body weight). (D) The progression of proteinuria from 6 to 8.5 weeks. (E) The level of BUN and serum creatinine at 8.5 weeks. WT, wild type; RASi, renin-angiotensin-system inhibitor; SGLT2i, Sodium-glucose-transporter-2 inhibitor; MRA, mineralocorticoid receptor antagonist.